Safe and Effective Standards of Care: Supporting the Administration of T-VEC for Patients With Advanced Melanoma in the Outpatient Oncology Setting

Wall, Lisa; Baldwin-Medsker, Abigail

doi:10.1188/17.cjon.e260-e266

“…Simultaneously, when the tumour cells lysed, the viruses within them are also released to infect and kill other tumour cells [28,29] to form a cascade ampli cation effect. In recent years, with increasing study, many types of OVs have been approved for marketing, such as H101 [30] approved in China, T-VEC [31] approved in the USA, and the Japanese herpes simplex virus Deltyact [32] . These marketed oncolytic virus drugs provide a good prospect and important motivation for the development of OVs.…”

Section: Discussionmentioning

confidence: 99%

Oncolytic adenovirus encoding LHPP exerts potent antitumor effect in lung cancer

Wang,

Zhao,

Wang

et al. 2024

Preprint

0

View full text Add to dashboard Cite

LHPP has been shown to be a new tumor suppressor, and has a tendency to be under-expressed in a variety of cancers. Oncolytic virotheray is a promising therapeutics for lung cancer in recent decade years. Here we successfully constructed a new recombinant oncolytic adenovirus GD55-LHPP and investigated the effect of GD55-LHPP on the growth of lung cancer cells in vitro and in vivo. The results showed that LHPP had lower expression in either lung cancer cells or clinical lung cancer tissues compared with normal cells or tissues, and GD55-LHPP effectively mediated LHPP expression in lung cancer cells. GD55-LHPP could effectively inhibit the proliferation of lung cancer cell lines and rarely affected normal cell growth. Mechanically, the oncolytic adenovirus GD55-LHPP was able to induce stronger apoptosis of lung cancer cells compared with GD55 through the activation of caspase signal pathway. Notably, GD55-LHPP also activated autophagy-related signal pathway. Further, GD55-LHPP efficiently inhibited tumor growth in lung cancer xenograft in mice and prolonged animal survival rate compared with the control GD55 or PBS. In conclusion, the novel construct GD55-LHPP provides a valuable strategy for lung cancer-targeted therapy and develop the role of tumor suppress gene LHPP in lung cancer gene therapy.

show abstract

“…After the tumour cells are lysed, the viruses within them are also released to infect and kill other tumour cells 26,27 , which forms a cascade amplification effect. In recent years, several types of OVs have been approved, such as H101 28 in China, T-VEC 29 in the USA, and the Japanese www.nature.com/scientificreports/ herpes simplex virus Deltyact 30 . These marketed OV drugs bring a good prospect and important motivation for the development of OVs.…”

Section: Discussionmentioning

confidence: 99%

Oncolytic adenovirus encoding LHPP exerts potent antitumor effect in lung cancer

Zhao,

Liu,

Zhan

et al. 2024

Sci Rep

0

View full text Add to dashboard Cite

LHPP has been shown to be a new tumor suppressor, and has a tendency to be under-expressed in a variety of cancers. Oncolytic virotheray is a promising therapeutics for lung cancer in recent decade years. Here we successfully constructed a new recombinant oncolytic adenovirus GD55-LHPP and investigated the effect of GD55-LHPP on the growth of lung cancer cells in vitro and in vivo. The results showed that LHPP had lower expression in either lung cancer cells or clinical lung cancer tissues compared with normal cells or tissues, and GD55-LHPP effectively mediated LHPP expression in lung cancer cells. GD55-LHPP could effectively inhibit the proliferation of lung cancer cell lines and rarely affected normal cell growth. Mechanically, the oncolytic adenovirus GD55-LHPP was able to induce stronger apoptosis of lung cancer cells compared with GD55 through the activation of caspase signal pathway. Notably, GD55-LHPP also activated autophagy-related signal pathway. Further, GD55-LHPP efficiently inhibited tumor growth in lung cancer xenograft in mice and prolonged animal survival rate compared with the control GD55 or PBS. In conclusion, the novel construct GD55-LHPP provides a valuable strategy for lung cancer-targeted therapy and develop the role of tumor suppress gene LHPP in lung cancer gene therapy.

show abstract

“…These data indicated that most detectable virus from evaluated sites waned by 7 days postexposure. 14,22 TVEC is classified as a BSL2-level agent at MSK, in accordance with FDA guidance, and this dictates preparation and environmental management for TVEC. Agent preparation by trained pharmacy personnel occurs in a negative-pressure room biosafety cabinent (BSC) using a closed transfer system.…”

Section: Tvec: Summary and Recommendations For Infection Preventionmentioning

confidence: 99%

“…Additionally, a dedicated contact isolation precaution indicator is placed in the patient's electronic medical record, which serves to alert staff to recent treatment with TVEC and the need for contact precautions. 22 Entry and removal of the indicator is undertaken by the clinical support teams. Precautions are instituted until all lesions are healed or scabbed as determined by direct observation at follow-up or day 7 following injection of TVEC, whichever is longer.…”

Section: Tvec: Summary and Recommendations For Infection Preventionmentioning

confidence: 99%

Viral oncolytic immunotherapy in the war on cancer: Infection control considerations

Robilotti

¹

,

Kumar

²

,

Glickman

³

et al. 2019

Infect. Control Hosp. Epidemiol.

View full text Add to dashboard Cite

Oncolytic viral immunotherapy is an emerging treatment modality for cancer that exploits in vivo replication and other viral properties to enhance immune killing of malignant cells. The potential for horizontal transmission of native or engineered oncolytic viruses creates several unique infection control challenges. In 2015, talimogene laherparepvec (TVEC) became the first agent in this class to gain FDA approval for treatment of melanoma, and several others are being developed. Although some data on the transmissibility of TVEC are available from clinical studies, the aftermarket or real-world experience remains limited. We conducted a PUBMED-based search of the medical literature focusing on the safety and risk of TVEC transmission to close contacts including healthcare workers. The findings are summarized in this review and are intended to provide infection preventionists with practical guidance on handling issues related to administration and care of patients receiving TVEC. Additionally, we describe the current mechanism for evaluating the risk related to similar new agents entering clinical trials at our institution. Development of standarized approaches for the safe administration and precautions for ongoing care, especially in immunocompromised patients, are essential to support the broad adoption of this novel therapy.

show abstract

Safe and Effective Standards of Care: Supporting the Administration of T-VEC for Patients With Advanced Melanoma in the Outpatient Oncology Setting

Cited by 5 publications

References 25 publications

Oncolytic adenovirus encoding LHPP exerts potent antitumor effect in lung cancer

Oncolytic adenovirus encoding LHPP exerts potent antitumor effect in lung cancer

Oncolytic adenovirus encoding LHPP exerts potent antitumor effect in lung cancer

Viral oncolytic immunotherapy in the war on cancer: Infection control considerations

Contact Info

Product

Resources

About